Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Glioma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Biogenea Pharmaceuticals Ltd, Thessaloniki, Greece
Study leads
Ioannis G Grigoriadis, Pharmacist
Study Director
Myoncotherapy